The effects of elevated glucose on cardiac function during hypoxia were investigated in isolated arterially perfused rabbit interventricular septa. Rest tension, developed tension, intracellular potential, 42K' efflux, lactate production, exogenous glucose utilization, and tissue high-energy phosphate levels were measured during a 50-min period of hypoxia with 4, 5, or 50 mM glucose present (isosmotically balanced with sucrose) and during reoxygenation for 60 min with perfusate containing 5 mM glucose/45 mM sucrose. At physiologic (4 or 5 mM) and supraphysiologic glucose (50 mM), lactate production and high-energy phosphate levels during hypoxia were equally well maintained, yet cardiac dysfunction was markedly attenuated by 50 mM glucose. Despite identical rates of total glycolytic flux, exogenous glucose utilization was enhanced by 50 mM glucose so that tissue glycogen levels remained normal during hypoxia, whereas glycogen became depleted with 4 or 5 mM glucose present during hypoxia. Most of the beneficial effects of 50 mM glucose occurred during the first 25 min of hypoxia. Prior glycogen depletion had no deleterious effects during hypoxia with 50 mM glucose present, but exacerbated cardiac dysfunction during hypoxia with 5 mM glucose present. These findings indicate that enhanced utilization of exogenous glucose improved cardiac function during hypoxia without increasing total glycolytic flux or tissue high-energy phosphate levels, suggesting a novel cardioprotective mechanism. (J.
Introduction
Beneficial effects of glucose on impaired cardiac function were recognized as early as 191 1, when Goulston (2) reported that ingestion of cane sugar improved symptoms of heart failure in seven patients. However, it was not until the studies of SodiPallares and co-workers in the 1 960s (3, 4) that the concept of using glucose in combination with insulin and potassium (GIK)' to improve cardiac function and limit myocardial inPortions ofthis work were previously presented in abstract form (1988. Circulation. 78[Suppl. 111I:I-261 [ 1] ). jury in the setting of ischemic heart disease gained widespread interest. Although most experimental studies demonstrated that glucose or GIK improved cardiac function and reduced injury during myocardial ischemia (5-12) or hypoxia (13) (14) (15) (16) (17) (18) , clinical studies have yielded conflicting results (4, (19) (20) (21) (22) (23) (24) (25) (26) . Some of the discrepancies may be related to the severity of ischemia, since in experimental studies the benefit of GIK during low-flow moderate ischemia was lost during severe ischemia (12), probably owing to more complete inhibition of anaerobic glycolysis and poorer delivery of substrate to the ischemic area. Both glucose alone and insulin alone have been shown to have beneficial effects (13, 14, 16, 26, 27) . The mechanism underlying the beneficial effects of these agents is not fully understood. Although facilitation of anaerobic glycolysis is the most obvious possibility, and is consistent with the observation that GIK increases glucose uptake during ischemia (5, 7, 9, 12) , some investigators (7, 9) have argued that the increase in total glycolytic flux is likely to be too modest to account for the improvement in cardiac function. These considerations have led to the hypothesis that the effects of GIK may be mediated by other factors besides increased high-energy phosphate production by enhanced anaerobic glycolysis. For example, GIK has consistently been found to lower circulating levels of free fatty acids, which are known to be deleterious in the setting of myocardial ischemia, and this action has been proposed as an alternate explanation for the beneficial effects of GIK (7, 9, 10) . Other potentially significant factors include preservation of cardiac glycogen stores (28-31), membrane-stabilizing effect of insulin (7, 27) , increased osmotic pressure (5) , and free radical scavenging effects of glucose (18) .
The purpose of the present study was to investigate in greater detail the metabolic effects of elevated glucose and insulin during hypoxia in order to determine whether direct metabolic effects of elevated glucose on anaerobic glycolysis underlie its well-documented beneficial effects on electromechanical function. We chose to study hypoxia for two major reasons: (a) more accurate measurements ofglycolytic flux are possible than during ischemia and (b) the beneficial effects of glucose on cardiac function during hypoxia have been unequivocally established (13) (14) (15) (16) (17) . Elevated potassium was not studied to avoid its complicating effects on membrane potential. The major finding is that cardiac dysfunction during hypoxia and after reoxygenation is closely related to exogenous glucose utilization, but not total glycolytic flux (exogenous glucose utilization plus glycogenolysis). During hypoxia net glycogenolysis appears to have deleterious consequences despite the fact that high-energy phosphate levels and total glycolytic flux are maintained. Possible mechanisms for this novel observation are discussed.
land White rabbits (2-3 kg) were heparinized and given an overdose of phenobarbital before thoracotomy. The heart was removed and the septal artery was cannulated. The well-perfused portion of the intraventricular septum was then isolated and mounted in a constant temperature (370C) nitrogen-filled chamber as described previously (32) . A suture placed at the apex of the septum was tied to a tension transducer to record tension. Rest tension was set at 4 g for all preparations. All septa were stimulated at 75 beats/min through a bipolar platinum electrode embedded in a corner of the preparation. A perfusion pump maintained constant flow of 370C perfusate through the septal artery at 1.75 ml/min. Venous effluent was collected at 5-min intervals during the experiment for metabolic assays through a polyethylene tube (PE-90) anchored at the base ofthe septum. Intracellular potential was monitored with floating glass microelectrodes filled with 3 M KCI as described previously (33) .
Standard perfusate was a modified Tyrode's solution consisting of 110 mM NaCl, 4 
Results
Effect of glucose on cardiac function during hypoxia. Fig. 1 compares tension, action potential duration, and lactate production in three typical preparations exposed to either 0, 5, or 50 mM glucose during a 50-min period ofhypoxia followed by reoxygenation for 1 h with Tyrode's solution containing 5 mM glucose. With 5 mM glucose present during hypoxia (middle tracing), a large contracture and decrease in developed tension occurred with incomplete recovery upon reoxygenation. Action potential duration also shortened significantly. Lactate production was maintained throughout hypoxia. In contrast, the functional abnormalities when 50 mM glucose was present in the hypoxic perfusate were much less severe (lower tracing). There was no contracture during hypoxia, less depression of developed tension, and better recovery of mechanical function recovery upon reoxygenation. Action potential duration was minimally shortened and lactate production was well maintained. It is noteworthy that despite the marked differences in electromechanical function with 5 mM and 50 mM glucose present during hypoxia, lactate production, the marker of anaerobic ATP production, was similar. For comparison, an example of hypoxia without glucose is also shown (upper tracing). Lactate production (lower graph) initially increased but then fell, accompanied by much more severe electromechanical dysfunction with no recovery following reoxygenation. tension after 1 h of reoxygenation was greater after hypoxia with 50 mM glucose present (to 84±3% ofcontrol) than with 5 mM glucose (52±4% of control, P < 0.005).
There was mild shortening of the action potential duration to 95±2% of control after 50 min with 50 mM glucose present during hypoxia (Fig. 2 , lower left panel). With 5 or 4 mM glucose action potential shortening during hypoxia was more marked, declining to 75±3% and 83±2% of control respectively (P < 0.01 compared to 50 mM glucose). Recovery of action potential duration after 60 min of reoxygenation was similar in all groups.
Despite the significant differences in electromechanical function during and after hypoxia with 50 and 5 or 4 mM glucose present, there were no significant differences in effluent lactate content during hypoxia between the groups ( Amol/g per min was reached within 10 min and maintained throughout the hypoxic period. To test the threshold at which lactate production was maintained during hypoxia, we also studied a group of seven hearts with 2.5 mM glucose in the hypoxic perfusate. At this glucose concentration lactate production was not maintained, falling to 0.58±0.15 ,umol/g per min after 50 min of hypoxia (P < 0.01 compared to 4, 5, Levels of high energy phosphates and cyclic AMP during hypoxia. To determine whether the beneficial effects of 50 mM glucose were associated with better preservation of cellular high-energy phosphate stores, levels of adenine nucleotides and creatine phosphate were measured at the end of hypoxic episode in the presence of 50, 5, and 4 glucose. Fig. 4 shows that there were no significant differences in high-energy phosphate levels between the different groups. These findings are consistent with the observation that total lactate production, the primary marker of high energy phosphate production during hypoxia, was the same in all three groups. Tissue levels of cyclic AMP were also measured and were similar in all the groups.
Exogenous glucose utilization during hypoxia. In light of large differences in electromechanical function during hypoxia and reoxygenation with 50 and 5 or 4 mM glucose present, the finding that total glycolytic flux and tissue high-energy phosphate levels were nearly identical indicates that enhancement oftotal anaerobic high-energy phosphate production could not explain the beneficial effects of high glucose during hypoxia. To further investigate the effects of glucose on anaerobic glycolysis during hypoxia we measured exogenous glucose utilization with [3H]glucose (Fig. 5) . In 18 preparations, the control rate of glucose utilization under oxygenated conditions was 0.12±0.010 Mpmol glucose/g per min. The ratio of glucose utilized to lactate produced was 0.63±0.05, indicating that a significant portion of lactate produced was being further metabolized oxidatively. During hypoxia glucose utilization increased ( could be accounted for by metabolism of exogenous g (since two lactate molecules are produced for each g molecule metabolized anaerobically). In contrast, durin oxia with either 5 or 4 mM glucose present, the ratio ofg utilized to lactate produced was 0.33±0.05 and 0.36: respectively (P < 0.001 for 5 vs. 50 and P < 0.05 for 4 mM glucose). A ratio below 0.5 indicates that a nonl glucose source, e.g., endogenous glycogen, was contribul lactate production. These results suggest that in the prese 50 mM glucose the total lactate produced during h) could be accounted for by metabolism of exogenous gl i.e., no net glycogenolysis occurred. In the presence of 5 mM glucose on the other hand, total glycolytic flux ( hypoxia was similar, but net glycogenolysis made a sign contribution (about 30%) to total lactate produced.
Tissue glycogen depletion during hypoxia. If the above results are correct, then tissue glycogen levels should remain normal during hypoxia with 50 mM glucose present, but become depleted with 5 or 4 mM glucose present during hypoxia. Fig. 6 shows that this was the case. In control experiments the (5) initial glycogen content was 118±5.3 ,gmol/g dry weight after (5) 30 min of equilibration in oxygenated Tyrode's solution and (5) fell to 67.2±5.2 ,umol/g after an additional period ofcontinued (8) aerobic perfusion of 2.5 h (equivalent to the average equilibration period + hypoxic period in the hypoxia experiments). In the hearts exposed to 50 mM glucose during hypoxia the glycogen level at the end of the hypoxic period was unchanged (68.5±9.1 gmol/g). In contrast, during hypoxia with 5 or 4 mM glucose in the perfusate glycogen content was significantly reduced at the end of the hypoxic period, to 42.9±4.0 and 48.2±3.5 gmol/g respectively (P < 0.05 control vs. 5 mM glucose, P not significant for control vs. 4 
mM glucose).
Effect ofglycogen depletion on cardiacfunction during hypoxia. Since above results indicate that glycogen depletion during hypoxia was associated with more severe electromechanical dysfunction and poorer recovery upon reoxygenation, the effects ofglycogen-depleting hearts before hypoxia was studied (Fig. 7) . Preparations were glycogen depleted by perfusion with oxygenated glucose-free perfusate for 1 h, which reduced developed tension by -50%. With 50 mM glucose present, glycogen-depleted preparations maintained lactate production during hypoxia and changes in rest tension, developed tension, or action potential duration shortening were almost identical to those in non-glycogen-depleted hearts. During hypoxia in the presence of 5 mM glucose, however, glycogen-depleted preparations tended to be more impaired than non-glycogendepleted preparations. Lactate production, after an initial increase similar to the non-glycogen-depleted hearts, dropped to 0.72±0.08 jmol/g per min after 50 min of hypoxia (P < 0.001 compared to non-glycogen-depleted hearts; Fig. 7 , lower right panel). The increase in rest tension was similar in both groups (Fig. 7, upper left panel) , although recovery after reoxygenation was slightly worse in glycogen-depleted hearts (6.6±0.7 vs. late 5.8±0.8 g, P not significant). Developed tension (Fig. 7 7 , lower left panel) shortened to a slightly greater extent in glycogen-depleted hearts (65±7% vs. 69±3% of control, P not significant). Although most of these differences did not achieve statistical significance, the trends suggest that glycogen stores are more important to the maintenance of cardiac function during hypoxia with 5 or 4 mM glucose present than with 50 mM glucose in the perfusate.
Effect of insulin during hypoxia. The effect of insulin on cardiac function during hypoxia in the presence of 5 mM glucose was also studied (Fig. 8) . In the absence of insulin preparations were unable to maintain lactate production during hypoxia, which fell to 0.75±11 umol/g per min at the end of the hypoxic period compared to 1.22±0.05 gmol/g per min with insulin present (P < 0.001; Fig. 8 cial effects on electromechanical cardiac function during and after recovery from hypoxia. The novel finding is that the improvement in cardiac function produced by elevated glucose during hypoxia was independent of total glycolytic flux and tissue high-energy phosphate content, but closely correlated with the rate of exogenous glucose utilization during hypoxia. At both physiologic (4 and 5 mM, or 72 and 90 mg%, respectively) and supraphysiologic (50 mM or 900 mg%), total glycolytic flux and tissue high-energy phosphate content were identical during hypoxia despite a marked attenuation in the severity of cardiac dysfunction at the high glucose concentration. The only metabolic difference identified between hypoxia with a physiologic or supraphysiologic glucose concentration was an increase in exogenous glucose utilization in the REST TENSION (4) These findings may shed some light on the controversy over whether the beneficial effects of elevated glucose are related to a direct effect on anaerobic glycolysis or to secondary metabolic and nonmetabolic sequelae. Although GIK increases glucose uptake during ischemia (5, 7, 9, 12), some investigators (7, 9) have argued that the increase in glycolytic flux is likely to be insufficient to account for the improvement in cardiac function. Although the metabolic effects of GIK appear to be highly dependent on the model of ischemia, the results of this study show that elevated glucose can have a direct metabolic effect on anaerobic glycolysis during hypoxia (i.e., enhance glucose utilization and prevent glycogenolysis) without increasing total glycolytic flux, and that this effect correlates with improved cardiac function.
To determine whether the beneficial effects of elevated glucose on cardiac function during hypoxia are related to its direct effects on anaerobic metabolism, it is important to exclude indirect effects of elevated glucose. Secondary metabolic and nonmetabolic mechanisms which could potentially contribute to the beneficial effects of GIK and its components during ischemia and hypoxia include the following: (a) lowering of circulating levels of free fatty acids (7, 9, 10) , which are known to be deleterious in the setting of myocardial ischemia, (b) preservation of cardiac glycogen stores (28-31), (c) membrane-stabilizing effects of insulin (7, 27) , (d) increased osmotic pressure (5), (e) free radical-scavenging effects of glucose (18, 43) , and (f) facilitation of high-energy phosphate production by a nonglycolytic pathway. Although these mechanisms may be important in other experimental models, their contribution to the beneficial effects ofglucose during hypoxia in the present study is probably not great. Fatty acid metabolism during hypoxia may be deleterious because of its oxygen-wasting effects and because it leads to accumulation toxic intermediates such as long chain acylcarnitines and acylcoenzyme A. However, recent work has shown that beneficial effects of inhibitors of fatty acid metabolism during ischemia may be related to their stimulation ofglucose metabolism since they did not reduce accumulation of these toxic intermediates (44) . We cannot absolutely exclude the possibility that 50 mM glucose exerted its beneficial effects by influencing endogenous fatty acid metabolism during hypoxia. However, this seems unlikely since exogenous fatty acids were not provided as a metabolic substrate in our experiments, metabolism of endogenous triglycerides and fatty acids should have been markedly suppressed by the very low perfusate oxygen tension, and 50 mM glucose did not improve cellular high-energy phosphate levels during hypoxia.
The hypothesis that a critical tissue level ofglycogen during hypoxia is necessary to support cardiac function is also not supported by our results. Although 50 mM glucose prevented net glycogenolysis during hypoxia, the beneficial effects of 50 mM glucose on cardiac function during hypoxia did not appear to depend on the tissue level of glycogen at the onset of hypoxia, since glycogen-depleted hearts tolerated hypoxia as well as non glycogen-depleted hearts in the presence of 50 mM glucose. Conversely, the tissue glycogen level at the onset of hypoxia was important to hearts exposed to 5 mM glucose during hypoxia. In this setting glycogen-depleted hearts tended to do worse than non-glycogen-depleted hearts, reflecting their dependence on endogenous glycogen to maintain total glycolytic flux. The latter result also indicates our method of glycogen depletion was effective. Although we did not quantitate the extent of glycogen depletion in the "glycogen-depleted" hearts, under similar conditions others have shown a > 50% reduction in tissue glycogen (31) , consistent with the -50% reduction in developed tension we observed in our "glycogendepleted" preparations.
Membrane-stabilizing effects of insulin could not explain the benefit of increased glucose concentration during hypoxia in our study since all of the hypoxic solutions contained the same concentration of insulin and there was still a benefit seen with 50 mM glucose. With 5 mM glucose present, removal of insulin was detrimental during hypoxia, but was also associated with a lower total glycolytic flux. In this case we could not determine whether the lack of insulin contributed to hypoxic cardiac dysfunction independently of its effect on total glycolytic flux.
In a few studies it has been suggested that the benefits of elevated glucose were due to an osmotic effect, since nonmetabolizable sugars were equally effective (5) and increased osmolarity is known to reduce ischemic dysfunction (45, 46) . Our findings are consistent with the majority of studies which have concluded that a benefit of GIK cannot be attributed exclusively to an osmotic effect (7, 11, 12, 16) , since osmolarity was balanced with sucrose in all of the solutions we used.
Glucose and other sugars are known to act as free radical scavengers, and could potentially reduce hypoxic injury by this mechanism (18, 43 Possible mechanisms underlying the superiority of exogenous glucose utilization at preserving cardiac function during hypoxia. Determining the. precise mechanism by which enhanced utilization of exogenous glucose improved cardiac function during hypoxia without increasing total glycolytic flux or tissue high-energy phosphate levels was beyond the scope of this study. However, assuming that the potential secondary effects of elevated glucose discussed above were not important, several possibilities are worth considering. First, cellular factors which control the proportions of total glycolytic flux derived from exogenous glucose vs. glycogen during hypoxia may also play a key role in modulating the susceptibility of the heart to electromechanical dysfunction. For example release of endogenous catecholamines during hypoxia may have been suppressed by supraphysiologic glucose concentrations. Cyclic AMP is known to have deleterious effects on cardiac function during myocardial ischemia (54, 55) and is also fundamentally involved in the activation of glycogenolysis. Since 50 mM glucose suppressed net glycogenolysis during hypoxia, it is reasonable to suppose that this effect was mediated by reduced levels of cyclic AMP. Carlsson (56) found that noradrenaline release during low flow ischemia was greater in hearts which were glycogen-depleted or exposed to glucose-free perfusate or to iodoacetate to inhibit glycolysis, although he did not compare physiologic and supraphysiologic glucose concentrations. Although we did not find any difference in tissue cyclic AMP levels after 50 min of hypoxia in hearts exposed to physiologic or 50 mM glucose, it is possible that significant differences were present at earlier times. This is a relevant possibility since most of the benefit of 50 mM glucose appeared to occur during the first 25 min of hypoxia (Fig.  9) (67) , and prevention of contracture during hypoxia has been reported to be preferentially dependent on glycolysis (68) . These findings may be relevant to our observation that rest tension was parameter of cardiac function most significantly benefited by 50 mM glucose during hypoxia (Fig. 2) Limitations andpotential relevance ofthe study to myocardial ischemia. In light of the increasingly interventional approaches being used in the treatment of ischemic heart disease syndromes, defining mechanisms by which cardioprotective strategies can be improved has become increasingly important. In attempting to relate the results of this study to more clinically relevant models ofmyocardial injury, however, a number of important limitations must be recognized. The rabbit septal preparation is an intrinsically low work preparation and, under normoxic conditions at physiologic coronary perfusion rates used in this study, aerobically metabolizes lactate derived from exogenous glucose to a lesser extent than more physiologic heart preparations (39) . This low rate of lactate metabolism, however, is not due to inadequate oxygen delivery since increasing flow rate has minor effects on lactate production and tension development despite several-fold increases in oxygen delivery (39) . Also during control aerobic perfusion, the preparation remains stable both functionally and metabolically for a number of hours (39, (69) (70) (71) , although tissue glycogen levels fall gradually over time (39) , as we have confirmed. Nevertheless we cannot exclude the possibility that the mechanisms underlying the benefits of elevated glucose during hypoxia in this preparation may not be operative in more physiologic models. More generally, observations in hypoxic muscle cannot necessarily be extrapolated to ischemia, the more clinically relevant situation. We also studied a very high concentration (50 mM) of glucose in order to maximize its metabolic effects and have not examined whether glucose concentrations in a more clinically attainable range (10-20 mM) have equivalent beneficial effects. Nevertheless, the finding that elevated glucose may benefit hypoxic myocardium by a direct metabolic effect without increasing total glycolytic flux raises the possibility that a similar effect may contribute to the beneficial effects of GIK therapy during myocardial ischemia.
